- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Pfizer Ratings Report.
The British pharma company suffers a setback with a lung-cancer drug it touted as a defense against a Pfizer takeover bid three years ago, and could be back in play.
The Justice Department is investigating the company's charitable contributions for kickbacks and false claims.
Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.